When Pfizer’s US sterile injectables facility at Rocky Mount was hit by a tornado last week, initial concerns over the immediate safety of staff were soon followed by speculation over potential shortages and disruptions to product availability, given the significance of the plant to the US supply chain.
The former Hospira facility in North Carolina is one of the largest sterile injectables manufacturing sites in the world, producing around a quarter of Pfizer’s sterile injectables – representing nearly 8% of those used in US hospitals
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?